2
Our top 10 articles for the year track seismic shifts across the pharmaceutical landscape, from high-level trade policy and drug pricing to fundamental regulatory stability and quality control. They highlight policy upheaval, regulatory complexity and quality control, and market disruption in both economics and therapy development. The industry faced intense pressure this year to adjust its global supply chains due to unprecedented tariffs, while simultaneously navigating new government efforts to mandate lower drug prices through most-favored-nation (MFN) deals. Regulatory bodies were defined by internal instability, such as abrupt leadership…